TDA, if you were GSK wouldn't you consider acquiring ACL ?
The market cap of ACL, at the moment, should be around $75m, so even if they had to pay a premium, this would offer an appealing payback - considering the revenue they will lose and all the other synergies they would be able to leverage.
If such a t/o (big pharma taking over biotech about to launch a competitive product) was to happen, would it be a first ? or would it be a "fairly usual" move ?
acl at investor conference - new york, page-2
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable